

Probiomics Limited ABN 97 084 464 193

Suite 1A, Level 2 802 Pacific Highway Gordon NSW 2072

P: +61 2 9844 5422 F: +61 2 9844 5445

W: www.probiomics.com.au

The Australian Stock Exchange Limited Companies Announcements Office SYDNEY

15 May 2009

RESULTS OF ANNUAL GENERAL MEETING RESOLUTIONS

Dear sirs,

This is to advise that all resolutions on the agenda for the general meeting held on 15 May 2009 were each passed by shareholders on a show of hands.

Proxies received for each resolution were as follows:-

Resolution 1: Approval to amend the terms of Convertible Note Deed

FOR 32,052,193
AGAINST 971,052
OPEN USABLE 366,217
ABSTAIN NIL

Resolution 2: Conversion of Convertible Notes.

FOR 36,036,193 AGAINST 737,052 OPEN USABLE 366,217 ABSTAIN 250,000

Yours truly,

Ashok Jairath

Company Secretary





Probiomics Limited

Probiomics has proprietary ownership of a unique probiotic strain – PCC®

PCC® has been clinically proved to have superior qualities to other probiotic strains – particularly in promoting systemic immune response.

Probiomics' commercial objective is to earn royalties from licensing PCC® to distribution companies selling products in global markets.

CONTACTS

Mr Ashok Jairath - Chief Financial Officer and Company Secretary Tel: 02 9844 5422 Email ashok.jairath@probiomics.com.au